DOCSLIB.ORG

Barbiturates I

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Barbiturates I Volume 6 | Issue 4 Article 7 1944 Barbiturates I. E. Peterson Iowa State College Follow this and additional works at: https://lib.dr.iastate.edu/iowastate_veterinarian Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Peterson, I. E. (1944) "Barbiturates," Iowa State University Veterinarian: Vol. 6 : Iss. 4 , Article 7. Available at: https://lib.dr.iastate.edu/iowastate_veterinarian/vol6/iss4/7 This Article is brought to you for free and open access by the Journals at Iowa State University Digital Repository. It has been accepted for inclusion in Iowa State University Veterinarian by an authorized editor of Iowa State University Digital Repository. For more information, please contact [email protected]. Barbiturates Their applicatiolls to veterinary therapeutics I. E. Peterson, '44 URING the last decade, a new group The barbiturates may be generally clas­ D of drugs, known as the barbiturates, sified as long or short acting, and the two has come into prominence in veterinary groups should not be used interchange­ medicine as hypnotics and anesthetics. ably. The choice of drug to be used de­ Today we find that these derivatives of pends on the type of patient, length of barbituric acid are used quite extensively time and rapidity of action desired, con­ in human medicine and in the small ani­ dition of the patient, and history of pre­ mal field of veterinary medicine. The vious medication. The barbiturates are therapeutic action of the derivatives of destroyed mostly in the liver and are ex­ this parent barbituric acid molecule, which creted to a certain extent by the kidneys. is weakly acid but has no sedative or In toxic doses, the respiratory system is hypnotic effect, has been made possible affected more quickly than is the cardiac because one or both of the hydrogens on system, but in animals which have a cir­ the side chains are replaceable. Thus, culatory disturbance, the barbiturates af­ barbital or diethyl barbituric acid was fect the heart and blood pressure even in obtained by replacing each hydrogen with light doses before the respiratory system an ethyl radical, forming a derivative shows any effects of overdosage. In gen­ which did possess hypnotic and sedative eral, the contraindications of the barbitu­ action. Similarly, by replacing one hydro­ rates are hepatic disease, renal impair­ gen with an ethyl radical and the other ment, circulatory disturbances, acidosis, with a phenyl radical, phenyl ethyl bar­ anemia, respiratory distress from any bituric acid or phenobarbital, was ob­ cause, toxemia, shocks, and previous ad­ tained. This had twice the potency of bar­ ministration of other sedatives, hypnotics, bital, yet possessed no greater toxicity. or anesthetics in large doses. Especially Further chemical research with barbituric those patients showing toxemia or shock acid produced pentobarbital or nembutal, should be watched very closely during by substituting an ethyl radical for one administration of the barbiturates for any hydrogen and a methyl-butyl group for idiosyncrasy to the drug. The barbiturates the other. This drug was not used phar­ are not usually considered to be habit macologically or clinically for many years forming in humans, but a few cases of this after it was first synthesized. An isomer occurrence have been reported. of pentobarbital called amytal, which had greater hypnotic effect, more rapid action, Advantages and faster elimination than pentobarbital, was produced by Shonle in 1920. The so­ The advantages of barbiturates are dium salts of these barbituric acid deriva­ enumerated as follows: tives were later shown to be more soluble 1. The degrees of action may be easily and more adapted to intravenous and in­ graded from very slightly sedative to com­ tramuscular injection, thus giving quicker plete anesthesia. and deeper, but shorter, effects. 2. The effect is very prompt, within a 198 The Veterinary Student few minutes after oral doses and imme­ and benezdrine sulfate. Picrotoxin seems diately after intravenous. to be quite superior due to its lasting ef­ 3. Full doses cause little effect on other fect but all of them must be given in re­ functions. peated dosage since they are eliminated 4. The respiratory system, circulation, from the body more quickly than the bar­ metabolism, and smooth muscle remain biturates. These should be supplemented almost normal until full toxic doses are by injections of hypertonic dextrose solu­ reached. tion and artificial respiration. The bar­ 5. Most of them have no serious after­ biturates have been used for euthanasia effects. in large doses to small animals and the 6. They produce no serious local ef­ younger large animals. The use for this fects so they may be administered by all purpose has been limited due to the cost channels. compared to that of saturated magnesium The disadvantages of the barbiturates sulfate solution. The barbiturates produce are the following: death without violent struggling as is 1. The response to the drug is not al­ seen in many other products used for this ways the same. purpose and thus are quite humane. 2. The hypnotic action is sometimes preceded by excitement, which is the rea­ Classification son for using a small dose of morphine in dogs before administering the barbitu­ The barbiturate drugs fall into two rates. general classifications, the short acting 3. As anesthetics they are administered group and slow acting group. The short at a single dose, thus making for error in acting group includes pentothal sodium, the concentration in the body, and they seconal sodium, pentobarbital sodium, require much safer handling when used amy tal, and sodium amy tal. This group for general anesthesia than when used as produces anesthesia very rapidly but is basal narcotics. short acting due to the rapid elimination 4. They require too large dosage and of the drug from the body. are therefore too expensive in large ani­ Pentothal sodium, or sodium ethyl thio­ mal practice. barbituric acid, is one of a series of new thiobarbiturates. It is rapidly destroyed Indications in the body, and although it is rapid in effect the duration of this effect is rela­ The barbiturates in general are indi­ tively short. It is an excellent anesthetic cated for the following conditions: for minor operations in small animals for 1. As a sedative in nervous conditions, the effect may be gone in 20 to 30 minutes. 2. As an analgesic in neuritis and pru­ The solution should be freshly made and ritis, slowly administered, a careful check be­ 3. To control nausea and vomiting, ing kept on the dose as injection proceeds. 4. As a motor depressant in convulsive When anesthesia is sufficiently advanced, states as in epilepsy, Glclampsia, and strych­ injection must cease; when the patient is nine poisoning, unconscious and respiration is shallow, 5. Preliminary to local anesthetics to anesthesia is usually present. The onset prevent accidents with cocaine and pro­ of anesthesia is usually so rapid that the caine, normal stages of anesthesia cannot be 0 b­ 6. As preanesthetic narcotic, and served during the administration of this 7. As anesthetics. drug. The dosage varies in different ani­ In poisoning with these drugs, respira­ mals; 7.0 to 11.0 mg. per pound body tory stimulants are used. The following weight injected intravenously with a drugs have been used as antidotes: picro­ standard dose of 10.0 mg. per pound of toxin or metrazol with ephedrine, picro­ body weight as an average is recom­ toxin, metrazol, ephedrine, coramine, mended. The anesthesia will persist for icoral, strychnine, caffeine, dinitrophenol, 25 to 30 minutes when an average dose of Spring, 1944 199 pentothal sodium is injected following the intramuscular inejction. The 5 percent administration of 8 to 32 mg. of morphine weight-volume solution is prepared with and 0.4 to 0.6 mg. of atropine to dogs. sterile water in the ampoule for this pur­ Seconal sodium has been used in human pose. Discard any solution of this drug medicine much more extensively than in which exhibits slight opalescence or hazi­ veterinary medicine. However, it is of ness. some value as a hypnotic when given in Pentobarbital sodium in preanesthetic small repeated doses to small animals for medication has many advantages similar the period of recovery is much shorter to those of sodium amy tal in which it re­ than that of the longer acting barbiturates. lieves preoperative apprehension by the This drug causes less renal disturbance patient, affords more quiet induction of than other members of the short acting anesthesia, reduces the amount of general group, thus being indicated in those pa­ anesthetic required, and diminishes the tients in which pentobarbital sodium postoperative nausea and vomiting in small would have a detrimental effect on the animals. In comparison to sodium amytal renal system. There are no after effects in preanesthetic medication, only one-half following the administration of this drug. the dose need be used to produce the same It has a large margin of safety in dosage effect and the period of postoperative re­ but larger doses seem to produce restless­ covery is only about one-half as long as ness rather than the desired hypnosis. that following the use of sodium amy tal. This drug is recommended for preanes­ Overdosage of either drug will produce thetic medication in small animals. The respiratory distress and postoperative rest­ dosage is usually 48 mg. to cats and small lessness, so one must caution against use dogs. Large doses followed by toxic re­ of barbiturates in doses sufficient to pro­ actions of the drug may be counteracted duce a deep preanesthetic effect for such by injection of hypertonic dextrose with doses predispose to respiratory embarrass­ caffeine and ephedrine. ment especially when they are supple­ mented with ether to the point of full Nembutal anesthesia.
Load more

Recommended publications
  • 162 Part 175—Indirect Food Addi
    § 174.6 21 CFR Ch. I (4–1–19 Edition) (c) The existence in this subchapter B Subpart B—Substances for Use Only as of a regulation prescribing safe condi- Components of Adhesives tions for the use of a substance as an Sec. article or component of articles that 175.105 Adhesives. contact food shall not be construed as 175.125 Pressure-sensitive adhesives. implying that such substance may be safely used as a direct additive in food. Subpart C—Substances for Use as (d) Substances that under conditions Components of Coatings of good manufacturing practice may be 175.210 Acrylate ester copolymer coating. safely used as components of articles 175.230 Hot-melt strippable food coatings. that contact food include the fol- 175.250 Paraffin (synthetic). lowing, subject to any prescribed limi- 175.260 Partial phosphoric acid esters of pol- yester resins. tations: 175.270 Poly(vinyl fluoride) resins. (1) Substances generally recognized 175.300 Resinous and polymeric coatings. as safe in or on food. 175.320 Resinous and polymeric coatings for (2) Substances generally recognized polyolefin films. as safe for their intended use in food 175.350 Vinyl acetate/crotonic acid copoly- mer. packaging. 175.360 Vinylidene chloride copolymer coat- (3) Substances used in accordance ings for nylon film. with a prior sanction or approval. 175.365 Vinylidene chloride copolymer coat- (4) Substances permitted for use by ings for polycarbonate film. 175.380 Xylene-formaldehyde resins con- regulations in this part and parts 175, densed with 4,4′-isopropylidenediphenol- 176, 177, 178 and § 179.45 of this chapter.
    [Show full text]
  • Salts of Therapeutic Agents: Chemical, Physicochemical, and Biological Considerations
    molecules Review Salts of Therapeutic Agents: Chemical, Physicochemical, and Biological Considerations Deepak Gupta 1, Deepak Bhatia 2 ID , Vivek Dave 3 ID , Vijaykumar Sutariya 4 and Sheeba Varghese Gupta 4,* 1 Department of Pharmaceutical Sciences, School of Pharmacy, Lake Erie College of Osteopathic Medicine, Bradenton, FL 34211, USA; [email protected] 2 ICPH Fairfax Bernard J. Dunn School of Pharmacy, Shenandoah University, Fairfax, VA 22031, USA; [email protected] 3 Wegmans School of Pharmacy, St. John Fisher College, Rochester, NY 14618, USA; [email protected] 4 Department of Pharmaceutical Sciences, USF College of Pharmacy, Tampa, FL 33612, USA; [email protected] * Correspondence: [email protected]; Tel.: +01-813-974-2635 Academic Editor: Peter Wipf Received: 7 June 2018; Accepted: 13 July 2018; Published: 14 July 2018 Abstract: The physicochemical and biological properties of active pharmaceutical ingredients (APIs) are greatly affected by their salt forms. The choice of a particular salt formulation is based on numerous factors such as API chemistry, intended dosage form, pharmacokinetics, and pharmacodynamics. The appropriate salt can improve the overall therapeutic and pharmaceutical effects of an API. However, the incorrect salt form can have the opposite effect, and can be quite detrimental for overall drug development. This review summarizes several criteria for choosing the appropriate salt forms, along with the effects of salt forms on the pharmaceutical properties of APIs. In addition to a comprehensive review of the selection criteria, this review also gives a brief historic perspective of the salt selection processes. Keywords: chemistry; salt; water solubility; routes of administration; physicochemical; stability; degradation 1.
    [Show full text]
  • SALTS of FATTY ACIDS
    SALTS of FATTY ACIDS Prepared at the 33rd JECFA (1988), published in FNP 38 (1988) and in FNP 52 (1992). Metals and arsenic specifications revised at the 55th JECFA (2000). An ADI 'not specified' was established at the 33rd JECFA (1988) SYNONYMS INS No. 470 DEFINITION These products consist of calcium, potassium or sodium salts of commercial myristic, oleic, palmitic, stearic, acids or mixtures of these acids from edible fats and oils. The article of commerce can be further specified by: - saponification value, - solidification point for the fatty acids obtained from the salts, - iodine value, - residue on ignition including assay of the cation, and - moisture content Assay Not less than 95% total fatty acid salts, dry weight basis DESCRIPTION Hard, white or faintly yellowish, somewhat glossy and crystalline solids or semi-solids or white or yellowish-white powder FUNCTIONAL USES Anticaking agent, emulsifier CHARACTERISTICS IDENTIFICATION Solubility (Vol. 4) Potassium and sodium salts are soluble in water and ethanol; calcium salts are insoluble in water, ethanol and ether Test for cations Heat 1 g of the sample with a mixture of 25 ml of water and 5 ml of hydrochloric acid. Fatty acids are liberated, floating as a solid or oil layer on the surface which is soluble in hexane. After cooling, aqueous layer is decanted and evaporated to dryness. Dissolve the residue in water and test for the appropriate cation. Fatty acid composition Using the Method of Assay, identify the individual fatty sample. The fatty acid(s) in primary abundance should conform to those declared on the label of the product PURITY Free fatty acids Not more than 3% Measure free fatty acids as directed in the method Free Fatty Acids.
    [Show full text]
  • The Use of Barbital Compounds in Producing Analgesia and Amnesia in Labor
    University of Nebraska Medical Center DigitalCommons@UNMC MD Theses Special Collections 5-1-1939 The Use of barbital compounds in producing analgesia and amnesia in labor Stuart K. Bush University of Nebraska Medical Center This manuscript is historical in nature and may not reflect current medical research and practice. Search PubMed for current research. Follow this and additional works at: https://digitalcommons.unmc.edu/mdtheses Part of the Medical Education Commons Recommended Citation Bush, Stuart K., "The Use of barbital compounds in producing analgesia and amnesia in labor" (1939). MD Theses. 730. https://digitalcommons.unmc.edu/mdtheses/730 This Thesis is brought to you for free and open access by the Special Collections at DigitalCommons@UNMC. It has been accepted for inclusion in MD Theses by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. THE USE OF THE BARBITAL COMPOUl~DS IN PRODUCING ANALGESIA AND .AMNESIA.IN LABOR Stuart K. Bush Senior Thesis Presented to the College of Medicine, University of Nebraska, Omaha, 1939 481021 THE USE OF THE BARBITAL COMPOUNDS IN PROLUCING ANALGESIA AND AMNESIA IN LABOR The Lord God said unto Eve, "I will greatly mul­ tiply thy sorrow and thJ conception; in sorrow thou shalt bring forth children." Genesis 3:lti Many a God-fearing man has held this to mean that any attempt to ease the suffering of the child­ bearing mother would be a direct violation of the Lord's decree. Even though the interpretation of this phrase has formed a great barrier to the advance­ ment of the practice of relieving labor pains, attempts to achieve this beneficent goal have been made at va­ rious times throughout the ages.
    [Show full text]
  • Managing Soil Salinity Tony Provin and J.L
    E-60 3-12 Managing Soil Salinity Tony Provin and J.L. Pitt* f your soil has a high salinity content, the plants ing may cause salts to accumulate in both surface growing there will not be as vigorous as they would and underground waters. The surface runoff of these Ibe in normal soils. Seeds will germinate poorly, dissolved salts is what gives the salt content to our if at all, and the plants will grow slowly or become oceans and lakes. Fertilizers and organic amendments stunted. If the salinity concentration is high enough, also add salts to the soil. the plants will wilt and die, no matter how much you water them. Effects of salts on plants Routine soil testing can identify your soil’s salinity As soils become more saline, plants become unable levels and suggest measures you can take to correct to draw as much water from the soil. This is because the specific salinity problem in your soil. the plant roots contain varying concentrations of ions (salts) that create a natural flow of water from the soil Salinity and salt into the plant roots. The terms salt and salinity are often used inter- As the level of salinity in the soil nears that of the changeably, and sometimes incorrectly. A salt is sim- roots, however, water becomes less and less likely to ply an inorganic mineral that can dissolve in water. enter the root. In fact, when the soil salinity levels are Many people associate salt with sodium chloride— high enough, the water in the roots is pulled back into common table salt.
    [Show full text]
  • Comparative Enhancing Effects of Phenobarbital, Amobarbital
    [CANCER RESEARCH 35,2884 2890, October 1975] Comparative Enhancing Effects of Phenobarbital, Amobarbital, Diphenylhydantoin, and Dichlorodiphenyltrichloroethane on 2-Acetylaminofluorene-induced Hepatic Tumorigenesis in the Rat Carl Peraino, R. J. Michael Fry, Everett Staffeldt, and John P. Christopher 2 Division of Biological and Medical Research, Argonne National Laboratory, Argonne, Illinois 60439 SUMMARY INTRODUCTION Earlier studies showed that phenobarbital feeding en- In earlier studies (27, 29), the prolonged feeding of hanced hepatic tumorigenesis in rats previously fed 2- phenobarbital to rats that had previously been fed AAF 3 for acetylaminofluorene for a brief period. As part of an a brief period markedly increased the subsequent incidence investigation of the mechanism of this enhancement, the of liver tumors. Using this sequential feeding regime, the present study evaluated the relative enhancing abilities of present study evaluated the relative tumorigenic enhancing amobarbital, diphenylhydantoin, and dichlorodiphenyltri- abilities of other compounds that, to varying degrees, chloroethane (DDT), agents that resemble phenobarbital to resemble phenobarbital in their effects on liver structure and varying degrees in their effects on liver structure and metabolism. The substances examined were amobarbital, metabolism. A comparison of hepatic tumor yields in rats diphenylhydantoin, and DDT. Table 1 compares relevant fed 2-acetylaminofluorene, followed by the test substance characteristics of these agents with those of phenobarbital, (sequential treatment), showed that amobarbital and di- reviewed previously (27, 29). Amobarbital is closest to phenylhydantoin had no enhancing activity, whereas the phenobarbital in structure and, like phenobarbital, alters enhancing effect of DDT was similar to that of phenobarbi- the metabolism of other drugs by the liver. Diphenylhydan- tal.
    [Show full text]
  • Use of Catalysts Comprising N-Substituted Cyclic Imides
    (19) & (11) EP 1 338 336 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: B01J 31/02 (2006.01) C07C 27/12 (2006.01) 04.04.2012 Bulletin 2012/14 C07C 33/20 (2006.01) C07C 49/78 (2006.01) C07C 51/21 (2006.01) C07C 51/265 (2006.01) (2006.01) (2006.01) (21) Application number: 01996429.5 C07C 55/14 C07C 63/04 C07C 63/06 (2006.01) C07C 63/26 (2006.01) C07C 63/313 (2006.01) C07D 213/80 (2006.01) (22) Date of filing: 08.11.2001 C07D 215/54 (2006.01) (86) International application number: PCT/JP2001/009767 (87) International publication number: WO 2002/040154 (23.05.2002 Gazette 2002/21) (54) USE OF CATALYSTS COMPRISING N-SUBSTITUTED CYCLIC IMIDES FOR PREPARING ORGANIC COMPOUNDS VERWENDUNG N-SUBSTITUIERTERRINGFÖRMIGER IMID ENTHALTENDER KATALYSATOREN ZUR HERSTELLUNG ORGANISCHER VERBINDUNGEN UTILISATION DE CATALYSEURS CYCLIQUES COMPRENANT DES IMIDES POUR LA PREPARATION DE COMPOSES ORGANIQUES (84) Designated Contracting States: (74) Representative: Grünecker, Kinkeldey, DE FR GB Stockmair & Schwanhäusser Anwaltssozietät (30) Priority: 15.11.2000 JP 2000348787 Leopoldstrasse 4 22.02.2001 JP 2001046986 80802 München (DE) (43) Date of publication of application: (56) References cited: 27.08.2003 Bulletin 2003/35 EP-A- 0 879 812 EP-A- 1 331 215 DD-A- 112 431 DE-C- 135 836 (73) Proprietor: Daicel Chemical Industries, Ltd. JP-A- 9 087 215 JP-A- 10 057 814 Kita-ku, JP-A- 11 226 416 Osaka-shi Osaka 530-0001 (JP) • TASHIRO, YASUTAKA ET AL: "A new strategy for thepreparation of terephthalic
    [Show full text]
  • Barbiturates for the Treatment of Alcohol Withdrawal Syndrome: ☆ a Systematic Review of Clinical Trials
    Journal of Critical Care 32 (2016) 101–107 Contents lists available at ScienceDirect Journal of Critical Care journal homepage: www.jccjournal.org Barbiturates for the treatment of alcohol withdrawal syndrome: ☆ A systematic review of clinical trials Yoonsun Mo, MS, Pharm.D., BCPS, BCCCP a,b,⁎, Michael C. Thomas, Pharm.D., BCPS, FCCP a,1, George E. Karras Jr., MD, FCCM b,2 a Department of Pharmacy Practice, Western New England University College of Pharmacy, 1215 Wilbraham Road, Springfield, MA 01119 b Mercy Medical Center, 271 Carew Street, Springfield, MA 01104 article info abstract Keywords: Purpose: To perform a systematic review of the clinical trials concerning the use of barbiturates for the treatment Barbiturates of acute alcohol withdrawal syndrome (AWS). Phenobarbital Materials and Methods: A literature search of MEDLINE, EMBASE, and the Cochrane Library, together with a man- Benzodiazepines ual citation review was conducted. We selected English-language clinical trials (controlled and observational Alcohol withdrawal syndrome studies) evaluating the efficacy and safety of barbiturates compared with benzodiazepine (BZD) therapy for Delirium tremens Systematic review the treatment of AWS in the acute care setting. Data extracted from the included trials were duration of delirium, number of seizures, length of intensive care unit and hospital stay, cumulated doses of barbiturates and BZDs, and respiratory or cardiac complications. Results: Seven studies consisting of 4 prospective controlled and 3 retrospective trials were identified. Results from all the included studies suggest that barbiturates alone or in combination with BZDs are at least as effective as BZDs in the treatment of AWS. Furthermore, barbiturates appear to have acceptable tolerability and safety pro- files, which were similar to those of BZDs in patients with AWS.
    [Show full text]
  • Original Article Effects of Repeated High Dosage of Chloral Hydrate and Pentobarbital Sodium Anesthesia on Hepatocellular System in Rats
    Int J Clin Exp Med 2015;8(7):10568-10576 www.ijcem.com /ISSN:1940-5901/IJCEM0008402 Original Article Effects of repeated high dosage of chloral hydrate and pentobarbital sodium anesthesia on hepatocellular system in rats Jianhong Yu1*, Xuehui Sun2*, Guifeng Sang3 1Department of Anesthesiology, Yuhuangding Hospital, Yantai 264000, China; 2Department of Rheumatology, Yuhuangding Hospital, Yantai 264000, China; 3Operating Room, Yuhuangding Hospital, Yantai 264000, China. *Equal contributors. Received March 24, 2015; Accepted July 2, 2015; Epub July 15, 2015; Published July 30, 2015 Abstract: This study aims to investigate the possible effects of repeated high dosage of chloral hydrate and pen- tobarbital sodium anesthesia on hepatocellular system in rats. Thirty Sprague Dawley rats were randomly divided into 3 groups: control group (group A), chloral hydrate group (group B) and pentobarbital sodium group (group C). Antioxidant enzymes superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), glutathione s transferase (GST) and catalase (CAT) activities and thiobarbituric acid-reactive substances (TBARS) level as well as serum biochemi- cal parameters alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and total bilirubin (T-BIL) were determined. Liver histopathological examinations were performed at termination. Furthermore, Bax and Bcl-2 expression, and caspase-3 activity were also evaluated. The SOD, GSH-Px, GST and CAT activities significantly decreased but TBARS levels increased in group B and C compared with group A. Hepatic injury was evidenced by a significant increase in serum ALT, AST and ALP activities in group B and C, which also con- firmed by the histopathological alterations. Moreover, administration of chloral hydrate and pentobarbital sodium could induce certain hepatic apoptosis accompanied by the upregulated Bax expression, the downregulated Bcl-2 expression and Bcl-2/Bax ratio, and the increase of caspase-3 activity.
    [Show full text]
  • Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: an American Academy of Sleep Medicine Clinical Practice Guideline Michael J
    pii: jc-00382-16 http://dx.doi.org/10.5664/jcsm.6470 SPECIAL ARTICLES Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline Michael J. Sateia, MD1; Daniel J. Buysse, MD2; Andrew D. Krystal, MD, MS3; David N. Neubauer, MD4; Jonathan L. Heald, MA5 1Geisel School of Medicine at Dartmouth, Hanover, NH; 2University of Pittsburgh School of Medicine, Pittsburgh, PA; 3University of California, San Francisco, San Francisco, CA; 4Johns Hopkins University School of Medicine, Baltimore, MD; 5American Academy of Sleep Medicine, Darien, IL Introduction: The purpose of this guideline is to establish clinical practice recommendations for the pharmacologic treatment of chronic insomnia in adults, when such treatment is clinically indicated. Unlike previous meta-analyses, which focused on broad classes of drugs, this guideline focuses on individual drugs commonly used to treat insomnia. It includes drugs that are FDA-approved for the treatment of insomnia, as well as several drugs commonly used to treat insomnia without an FDA indication for this condition. This guideline should be used in conjunction with other AASM guidelines on the evaluation and treatment of chronic insomnia in adults. Methods: The American Academy of Sleep Medicine commissioned a task force of four experts in sleep medicine. A systematic review was conducted to identify randomized controlled trials, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process was used to assess the evidence. The task force developed recommendations and assigned strengths based on the quality of evidence, the balance of benefits and harms, and patient values and preferences.
    [Show full text]
  • Article on Relative Abuse Liability of Triazolam
    Neuroscience & giobehaviora[Reviews. Vol. 9, pp. 133-151. 19_5. e Ankho International Inc. Printed in the U.S.A 0149-7634/85 5300 ÷ 00 Relative Abuse Liability of Triazolam: Experimental Assessment in Animals and Humans ROLAND R. GRIFFITHS,** RICHARD J. LAMB,* NANCY A. ATOR,* JOHN D. ROACHE* AND JOSEPH V. BRADY** Departments of *Psychiatry and tNeuroscience. The Johns Hopkins University School of Medicine 720 Rutland Avenue, Baltimore, MD 21205 GRIFFITHS, R. R., R. J. LAMB, N. A. ATOR, J. D. ROACHE AND J. V. BRADY. Relative abuse liability oftriazolam: Experimental assessment in animals and humans. NEUROSCI BIOBEHAV REV 9(1) 133--151. 1985.--The abuse liability of a drug is a positive, interactive function of the reinforcing and adverse effects of the drug. The relative abuse liability of the hypnotic henzodiazepine, triazoiam, has been controversial. This paper reviews animal and human studies beating on its relative abuse liability, including data on pharmacological profile, reinforcing effects, liking, speed of onset, discrimina- tive stimulus effects, subjective effects, physiological dependence, rebound and early morning insomnia, drug produced anxiety, lethality in overdose, psychomotor impairment, interactions with ethanol anterogr_e amnesia, impaired aware- ness of drug effect, and other psychiatric and behavioral disturbances. It is concluded that the abuse liability of triazolam is less than that of the intermediate duration barbiturates such as pentobarbital. Although there are considerable data indicating similarities of triazolam to other benzodiazepines, there is also substantial speculation among clinical inves- til_tors and some limited data suggesting that the abuse liability of triazolam is greater than that of a variety of other benzodiazepines, and virtually no credible data or speculation that it is less.
    [Show full text]
  • Use of Sodium Salts in the Purification of Clays and in the Casting Process
    DEPARTMENT OF COMMERCE Technologic Papers of THE Bureau of Standards S. W. STRATTON, Director No. 51 USE OF SODIUM SALTS IN THE PURIFICATION OF CLAYS AND IN THE CASTING PROCESS BY A. V. BLEININGER, Ceramic Chemist Bureau of Standards [ISSUED SEPTEMBER 25, 1915] WASHINGTON GOVERNMENT PRINTING OFFICE 1915 ADDITIONAL COPIES OF THIS PUBLICATION MAY BE PROCURED FROM THE SUPERINTENDENT OF DOCUMENTS GOVERNMENT PRINTING OFFICE WASHINGTON, D. C. AT 15 CENTS PER COPY V • * • • • • • • • • • • .; • « * • • • • • • • • * . • • ... USE OF SODIUM SALTS IN THE PURIFICATION OF CLAYS AND IN THE CASTING PROCESS By A. V. Bleininger CONTENTS Page I. Introduction 3 II. Effect of alkalies upon the sedimentation of clays 6 1 General principles 6 2. Use of alkaline compounds in the washing of clay 8 III. Results obtained in treating several clays 10 1 Georgia kaolin 10 2 North Carolina kaolin 11 3. Florida kaolin n 4. Tennessee ball clay No. 3 12 5. General effect of deflocculation upon color 13 6. Effect upon drying and burning shrinkages 13 IV. Electrical separation of clay 14 1. General description 14 2. Theory of process 14 3. Stages of electrical separation 16 4. Results of electrical separation experiments 16 5. Generalization, based on results obtained 19 V. Function of the alkalies in the casting process 19 1 Viscosity of slips 19 2 Outline of work 22 VI. Effect of various amounts of sodium carbonate and sodium silicate 23 1. North Carolina kaolin body 23 2. Georgia kaolin body 25 3. Tennessee ball clay body 26 4. Florida kaolin body 26 VII. Viscosity of clay mixtures without addition of alkali 31 VIII.
    [Show full text]